Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

NCT00366704 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: bifeprunox
DRUG: risperidone

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Collaborators

[object Object]